Literature DB >> 36241959

Evaluation of the Efficacy of Amphotericin B and Terbinafine Microemulsions and Their Combination on Cutaneous Leishmaniasis and Comparison with the Conventional Drug Form in BALB/c Mice.

Zeynab Baharvandi1,2, Anayatollah Salimi3,4, Reza Arjmand2, Ali Jelowdar5,6, Abdollah Rafiei1,2.   

Abstract

Intracellular parasitic protozoa of Leishmania sp. causes leishmaniasis. The restricted access of the drugs to affected cells in the treatment of intracellular infections such as leishmaniasis is frequently hampered. Furthermore, most of today's drugs have limited uses due to some containing toxic compounds, and drug resistance is on the rise. In the present investigation, Amphotericin B (AmB) and Terbinafine (Tbf) were loaded in microemulsion (ME) in combination and alone, and the in vivo efficacy was considered in BALB/c mice infected with Leishmania major (L. major). The wound size at the base of the mouse tail was measured, and real-time PCR was performed to quantify the parasite load after the infection challenge. The study demonstrated that the ME-AmB and ME-Tbf formulations are safe and effective compounds for the treatment of cutaneous leishmaniasis by enhancing the effectiveness of AmB and Tbf in reducing the parasite burden.
© 2022. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.

Entities:  

Keywords:  amphotericin B; cutaneous leishmaniasis; leishmania  terbinafine; microemulsion; terbinafine

Mesh:

Substances:

Year:  2022        PMID: 36241959     DOI: 10.1208/s12249-022-02435-1

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   4.026


  23 in total

Review 1.  Leishmaniasis: treatment updates and clinical practice guidelines review.

Authors:  Nathanial K Copeland; Naomi E Aronson
Journal:  Curr Opin Infect Dis       Date:  2015-10       Impact factor: 4.915

Review 2.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis.

Authors:  M L Rodrigues; R S Costa; C S Souza; N T Foss; A M Roselino
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1999 Jan-Feb       Impact factor: 1.846

Review 4.  Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa.

Authors:  C W Roberts; R McLeod; D W Rice; M Ginger; M L Chance; L J Goad
Journal:  Mol Biochem Parasitol       Date:  2003-02       Impact factor: 1.759

Review 5.  Leishmaniasis drug discovery: recent progress and challenges in assay development.

Authors:  Bilal Zulfiqar; Todd B Shelper; Vicky M Avery
Journal:  Drug Discov Today       Date:  2017-06-21       Impact factor: 7.851

6.  Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.

Authors:  Shyam Sundar; Himanshu Mehta; A V Suresh; Shri P Singh; Madhukar Rai; Henry W Murray
Journal:  Clin Infect Dis       Date:  2004-01-13       Impact factor: 9.079

7.  Miltefosine for new world cutaneous leishmaniasis.

Authors:  J Soto; B A Arana; J Toledo; N Rizzo; J C Vega; A Diaz; M Luz; P Gutierrez; M Arboleda; J D Berman; K Junge; J Engel; H Sindermann
Journal:  Clin Infect Dis       Date:  2004-04-09       Impact factor: 9.079

8.  Leishmaniasis worldwide and global estimates of its incidence.

Authors:  Jorge Alvar; Iván D Vélez; Caryn Bern; Mercé Herrero; Philippe Desjeux; Jorge Cano; Jean Jannin; Margriet den Boer
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

9.  Structural basis for selective targeting of leishmanial ribosomes: aminoglycoside derivatives as promising therapeutics.

Authors:  Moran Shalev; Haim Rozenberg; Boris Smolkin; Abedelmajeed Nasereddin; Dmitry Kopelyanskiy; Valery Belakhov; Thomas Schrepfer; Jochen Schacht; Charles L Jaffe; Noam Adir; Timor Baasov
Journal:  Nucleic Acids Res       Date:  2015-08-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.